Zusammenfassung
Die Erkrankung des Herzmuskels ist die wichtigste kardiovaskuläre Manifestation einer HIV Infektion. Mit Zunahme der Lebenserwartung der Patienten wird ihre Prävalenz wahrscheinlich zunehmen. Sie kann sich als Myokarditis, als dilatative Kardiomyopathie, oder als isolierte Dysfunktion des linken oder rechten Ventrikels manifestieren. Die myokardiale Beteiligung bei einer HIV Infektion ist multifaktoriell: Sie kann eine Folge der myokardialen Invasion mit HIV selbst sein, aber auch auf Grund von opportunistischen Infekten, Virusinfektionen, autoimmunen Reaktionen auf eine Virusinfektion, einer medikamentös bedingten Kardiotoxizität, Unterernährung, sowie als Folge der lang andauernden Immunsuppression entstehen. Sowohl Kinder als auch Erwachsene sind betroffen. Der Schweregrad des myokardialen Befalls reicht vom autoptischen Zufallsbefund mikroskopisch sichtbarer myokardialer Entzündung bis zur klinisch wirksamen Herzerkrankung mit chronischer kardialer Funktionsstörung. Die Prognose ist schlecht und resultiert bei 5% aller HIV Patienten im symptomatischen Herzversagen. Studien aus der Zeit vor der Einführung der hoch aktiven antiretroviralen Therapie (HAART) zeigen eine ungefähr 30%ige Prävalenz einer Kardiomyopathie bei Patienten mit AIDS. Die HAART hat den Verlauf der HIV-Erkrankung deutlich verändert: die Überlebenszeit wurde verlängert und die Lebensqualität der mit HIV infizierten Patienten wurde verbessert. Gute Evidenz deutet darauf hin, dass die HAART auch das Vorkommen der kardiovaskulären Manifestationen einer HIV Infektion significant reduziert. Im Vergleich zur "Prä-HAART-Ära" wurde die Prävalenz der HIV assoziierten Kardiomyopathie durch HAART um fast das 7-fache reduziert. Dies wird als Folge der Vermeidung von opportunistischen Infektionen und der Reduktion des Auftretens einer Myokarditis aufgefasst. Die HAART steht allerdings nur einer Minderheit der mit HIV infizierten Individuen zur Verfügung. In den meisten Gebieten der Welt gelten heute noch die in der "Prä-HAART-Ära" erhobenen Prävalenzdaten. In der vorliegenden Übersicht werden die Ätiologie, die Pathogenese und die Klinik der HIV-assoziierten myokardialen Erkrankung dargestellt und Maßnahmen zur Überlebensverbesserung diskutiert.
Summary
Heart muscle disease is the most important cardiovascular manifestation of HIV infection and is likely to become even more prevalent as HIV infected patients live longer. This may present as myocarditis, dilated cardiomyopathy or isolated left or right ventricular dysfunction. Myocardial involvement in HIV infection is multifactorial and may arise as a result of myocardial invasion with HIV itself, opportunistic infections, viral infections, autoimmune response to viral infection, drug-related cardiac toxicity, nutritional deficiencies, and prolonged immunosuppression. Both adults and children are affected with severity ranging from incidental microscopic inflammatory findings at autopsy to clinically significant cardiac disease with chronic cardiac dysfunction. It is associated with a poor prognosis, and results in symptomatic heart failure in up to 5% of HIV patients. Clinical pathological studies from the pre-HAART era show a 30% prevalence of cardiomyopathy in patients with AIDS. The introduction of highly active antiretroviral therapy (HAART) regimens has substantially modified the course of HIV disease by lengthening survival and improving quality of life of HIV-infected patients. There is also good evidence that HAART significantly reduces the incidence of cardiovascular manifestations of HIV infection. By preventing opportunistic infections and reducing the incidence of myocarditis, HAART regimens have reduced the prevalence of HIV-associated cardiomyopathy by almost 7-fold from the pre-HAART era. HAART is however only available to a minority of HIV infected individuals in most areas of the world and studies from the pre-HAART period still apply. In this review, the aetiopathogenesis and presentation of HIV related myocardial disease were reviewed and measures taken to improve survival discussed.
Article PDF
Avoid common mistakes on your manuscript.
References
Sani MU, Okeahialam BN, Aliyu SH, Enoch DA (2005) Human Immunodeficiency Virus (HIV) related heart disease: a review. Wien Klin Wochenschr 117: 73–81
Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 25: 2405–2418
Currie PF, Boon NA (2003) Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 17 [Suppl 1]: S21–S28
Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bicker JT, et al (2000) Cardiac dysfunction and mortality in HIV-infected children. The prospective P2C2 HIV multicenter study. Circulation 102: 1542–1548
Prendergast BD (2003) HIV and cardiovascular medicine. Heart 89: 793–800
Levy WS, Simon GL, Rios JC, Ross AM (1989) Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 63: 86–89
Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G (1998) Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N Engl J Med 339: 1093–1099
Barbaro G, Barbarini G, Di Lorenzo G (1996) Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: a multicenter echocardiographic and echo-Doppler study. Aids Res and Hum Retroviruses 12: 1559–1563
Corallo S, Mutinelli MR, Moroni M, Lazzarin A, Celano V, Rappossini A, et al (1988) Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur Heart J 9: 887–892
Barbaro G (1999) Dilated cardiomyopathy in the acquired immunodeficiency syndrome. Eur Heart J 20: 629–630
Sani MU, Okeahialam BN (2005) Epidemiology and pathogenesis of HIV related heart disease: a review. Nig J Med 14: 255–260
Barbaro G, Lipshultz SE (2001) Pathogenesis of HIV-associated cardiomyopathy. Ann NY Acad Sci 946: 57–81
Hajjar LA, Calderaro D, Yu PC, Guiliano I, de Oliviera LEM, Barbaro G, et al (2005) Cardiovascular manifestations in patients infected with the human immunodeficiency virus Arq. Bras Cardiol 85: 363–377
Barbaro G, Fisher SD, Lipshultz SE (2001) Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 1: 115–124
Barbaro G, Di Lorenzo G, Soldini M, Giancasparo G, Grisorio B, Pellicelli AM, et al (1999) Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus associated cardiomyopathy. Circulation 100: 933–939
Calabarese LH, Proffitt MR, Yen-Lieberman B, Hobbs RE, Ratliff NB (1989) Congestive cardiomyopthy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann Intern Med 107: 691–692
Cenacchi G, Re MC, Furlini G, La Placa M, Binetti G, Rapezzi C, et al (1990) Human immunodeficiency virus type I antigen detection in endomyocardial biopsy: an immunomorphological study. Microbiologica 13: 145–149
Grody WW, Cheng L, Lewis W (1990) Infection of the heart by the HIV. Am J Cardiol 66: 203–206
Jacob AJ, Rebus S, Bird AG (1992) Can HIV infect the heart? Eur Heart J 13: 370
Herskowitz A, Willoughby S, Wu TC, Beschorner WE, Neumann DA, Rose NR, et al (1993) Immunopathogenesis of HIV-1 associated cardiomyopathy. Clin Immunol Immunopathol 68: 234–241
Brooke S, Chan R, Howard S, Sapolsky R (1997) Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex. Proc Natl Acad Sci 94: 9457–9462
Del Corno M, Liu QH, Schols D, de Clercq E, Gessani S, Freedman BD, et al (2001) HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 98: 2909–2916
Medina I, Ghose S, Ben-Ari Y (1999) Mobilization of intracellular calcium stores participates in the rise of [Ca2+] and the toxic actions of the HIV coat protein GP120. Eur J Neurosci 11: 1167–1178
Kan H, Finkel MS (2001) Interactions between cytokines and neurohormonal systems in the failing heart. Heart Fail Rev 6: 119–127
Sugden PH, Clerk A (1998) "Stress-responsive" mitogenactivated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83: 345–352
Mackay K, Mochly-Rosen D (2000) Involvement of a p38 mitogenactivated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. J Mol Cell Cardiol 32: 1585–1588
Cook SA, Sugden PH, Clerk A (1999) Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 31: 1429–1434
Liao P, Wang SQ, Wang S, Zheng M, Zheng M, Zhang SJ, et al (2002) p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 90: 190–196
Kan H, Xie Z, Finkel MS (2004) p38 MAP kinase-mediated negative inotropic effect of HIV gp120 on cardiac myocytes. Am J Physiol Cell Physiol 286: C1–C7
Ginsburg R, Bristow MR, Billingham ME, Stinson EB, Schroeder JS, Harrison DC (1983) Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J 106: 535–540
Zheng M, Zhang SJ, Zhu WZ, Ziman B, Kobilka BK, Xiao RP (2000) β2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or Gs in adult mouse cardiomyocytes. J Biol Chem 275: 40635–40640
Magne S, Couchie D, Pecker F, Pavoine C (2001) β2-Adrenergic receptor agonists increase intracellular free Ca2+ concentration cycling in ventricular cardiomyocytes through p38 and p42/44 MAPK-mediated cytosolic phospholipase A2 activation. J Biol Chem 276: 39539–39548
Horn EM, Bilezikian JP (1990) Mechanisms of abnormal transmembrane signaling of the beta-adrenergic receptor in congestive heart failure. Circulation 82 [Suppl]: I26–I34
Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, et al (2004) HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 4: 327–337
Restrepo CS, Diethelm L, Lemos JA, Velasquez E, Ovella TA, Martinez S, et al (2006) Cardiovascular complications of human immunodeficiency virus infection. RadioGraphics 26: 213–231
Klatt EC, Meyer PR (1988) Pathology of the heart in AIDS. Arch Pathol Lab Med 122: 114
Anderson D, Virmani R, Reilly JM, O' Leary T, Cunnion RE, Robinowitz M, et al (1988) Prevalent myocarditis at necropsy in AIDS. J Am Coll Cardiol 11: 729–739
Niedt GW, Schinella RA (1985) Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 109: 727–734
Kaul S, Fishbein MC, Siegel RJ (1991) Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. Am Heart J 122: 535–544
Dittrich H, Chow L, Denaro F, Spector S (1988) Human immunodeficiency virus, coxsackievirus, and cardiomyopathy (letter). Ann Intern Med 108: 308–309
Hofman P, Drici MD, Gibelin P, Michiels JF, Thyss A (1993) Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. Br Heart J 70: 376–380
Grimmes MM, La Pook JD, Bar MH, Wasserman HS, Dwork A (1987) Disseminated pneumocystis carinii infection in a patient with AIDS. Hum pathol 18: 307–308
Lewis W, Grody WN (1992) AIDS and the heart: review and consideration of pathogenic mechanisms. Cardiovasc Pathol 1: 53–64
Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ (1986) Cryptococcal disease in patients with AIDS: diagnostic features and outcome of treatment. Ann Inter Med 104: 234–240
Lafont A, Wolff M, Marche C, Clair B, Regnier B (1987) Overwhelming myocarditis due to Cryptococcus neoformans in an AIDS patients. Lancet 2: 1146–1146
Cox JN, di Dio F, Pizzolato GP, Lerch R, Pochon N (1990) Aspergillus endocarditis and myocarditis in a patient with AIDS. Virchows Archiv [A] 417: 255–259
Barbaro G, Di Lorenzo G, Soldini M, Giancasparo G, Grisorio B, Pellicelli AM, et al (2000) Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of TNF-α and iNOS. AIDS 14: 827–838
Barbaro G (2001) Cardiovascular manifestations of HIV infection. J R Soc Med 94: 384–390
Ho DD, Pomerantz RT, Kaplan JC (1987) Pathogenesis of infection with HIV. N Engl J Med 317: 278–286
Rodriguez ER, Nasim S, Hsia J, Sandin RL, Ferreira A, Hilliard BA, et al (1991) Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue. Am J Cardiol 68: 1511–1520
Factor SM, Sonnenblick EH (1985) The pathogenesis of clinical and experimental congestive cardiomyopathies and recent concepts. Prog cardiovasc Dis 27: 395–420
Sardesai SH, Mourant AJ, Sivathandon Y, Farrow R, Gibbons DO (1990) Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure. Br Heart J 63: 234–237
Freeman R, Roberts MS, Friedman LS, Broadbridge C (1990) Autonomic function and HIV infection. Neurology 40: 575–580
Glulio L, Petrucci T, Patrizio M, Bernado A (1991) HIV envelope glycoprotein (gp 120) interacts with astroglial beta adrenergic receptors. Int Conf AIDS. Florence, abstract No MA 1037
Barbaro G, Pellicelli A, Barbarini G, Akashi YJ (2006) Takotsubo-like left ventricular dysfunction in an HIV-infected patient. Curr HIV Res 4: 239–241
Akashi YJ, Musha H, Kida K, Itoh K, Inoue K, Kawasaki K, et al (2005) Reversible ventricular dysfunction takotsubo cardiomyopathy. Eur J Heart Fail 7: 1171–1176
Hoffman M, Lipshultz SE, Miller TL (1999) Malnutrition and cardiac abnormalities in the HIV-infected patients. In: Miller TL, Gorbach S (eds) Nutritional aspects of HIV infection. Arnold, London, pp 33–39
Jacob AJ, Fell GS, Boon NA (1992) Is HIV cardiomyopathy related to deficiency of selenium? Br Heart J 68: 137–142
Dworkin BM, Antonecchia PP, Smith F, Weiss L, Davidian M, Rubin D, et al (1989) Reduced cardiac selenium content in AIDS. J Parentre Enter Nutr 13: 644–647
Zazzo JF, Chalas J, Lafont A, Camus F, Chappuis P (1988) Is non obstructive cardiomyopathy in AIDS a selenium deficiency related disease? J Parenter Enter Nutr 12: 337–338
Twagirumukiza M, Nkeramihigo E, Seminega B, Gasakure E, Boccara F, Barbaro G (2007) Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 5: 129–137
Miller TL, Orav EJ, Colan SD, Lipshultz SE (1997) Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr 66: 660–664
Beach RS, Mantero-Atienza E, Shor-Posner G, Javier JJ, Szapocznik J, Morgan R, et al (1992) Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS 6: 701–708
Baum MK, Mantero-Atienza E, Shor-Posner G, Fletcher MA, Morgan R, Eisdorfer C, et al (1991) Association of Vit B6 status with parameters of immune function in early HIV-1 infection. J Acq Immune Def Syndr 4: 1122–1132
Schocken DD, Holloway TD, Powers PS (1989) Weight loss and the heart: effects of anorexia nervosa and starvation. Arch Intern Med 149: 877–881
Fantoni M, Autore C, Del Borgo C (2001) Drugs and cardiotoxicity in HIV and AIDS. Ann NY Acad Sci 946: 179–199
Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlett JD (1992) Cardiomyopathy associated with anti-retroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 116: 311–313
Sonnenblick M, Rosin A (1991) Cardiotoxicity of interferon: a review of 44 cases. Chest 99: 557–561
Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88: 168–175
Brown DL, Sather S, Cheitlin MD (1993) Reversible cardiac dysfunction associated with foscarnet for cytomegalovirus esophagitis in an AIDS patient therapy. Am Heart J 125: 1439–1441
Arsura EL, Ismail Y, Freeman S, Karunakar AR (1994) Amphotericin B induced cardiomyopathy. Am J Med 97: 560–562
Cheitlin MD, Schiller NB, Kee L, et al (1990) Longitudinal echocardiographic AIDS project: effect of substance abuse on left ventricular function. Int Conf AIDS, San Francisco, Abstract No FB 529
Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G (2000) The effects of HIV infection on endothelial function. Endothelium 7: 223–242
Herskowitz A, Neuman DA, Ansari AA (1993) Concepts of autoimmunity applied to idiopathic dilated cardiomyopathy. J Am Coll Cardiol 22: 1385–1388
Autran BR, Gorin I, Leibowitch M Laroche L, Escande JP, Hewitt J, et al (1983) AIDS in a Haitian woman with cardiac Kaposi's sarcoma and Whipple's disease. Lancet 1: 767–768
Herskowitz A, Willoughby SB, Vlahov D, Baughman KL, Ansari AA (1995) Dilated heart muscle disease associated with HIV infection. Eur Heart J 16: 50–55
Barbaro G (2001) HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 344: 1799–1800
Otedo AE, Oyoo GO, Obondi JO, Otieno CF (2005) Vasculitis in HIV: report of eight cases. East Afr Med J 82: 656–659
Mondal D, Pradhan L, Ali M, Agrawal KC (2004) HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 4: 287–302
Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63–F70
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093–2099
Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al (2003) Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179–1193
Welch K, Finkbeiner W, Alpers CE, Blumenfeld W, Davis RL, Smuckler EA, et al (1984) Autopsy findings in the acquired immunodeficiency syndrome. JAMA 252: 1152–1159
Mocroft A, Phillips AN, Lundgren JD (2004) HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med 140: 578–579
Biggar RJ, Rabkin CS (1992) The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr Opin Oncol 4: 883–893
Dalli E, Quesada A, Paya R (1990) Cardiac involvement by non-Hodgkin's lymphoma in acquired immunodeficiency syndrome. Int J Cardiol 26: 223–225
Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, et al (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1: 3–14
Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G (1998) Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 14: 1071–1077
Levy WS, Simon GL, Rios JC, Ross AM (1989) Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 63: 86–89
Sani MU, Okeahialam BN, Ukoli CO (2004) Electrocardiographic abnormalities in Nigerian AIDS patients. Trop Card 30: 3–6
Levy WS, Vargheese PJ, Anderson DW, Leiboff RH, Orenstein JM, Virmani R, et al (1988) Myocarditis diagnosed by endomyocardial biopsy in HIV infection with cardiac dysfunction. Am J Cardiol 62: 658–659
Ntsekhe M, Hakim J (2005) Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 112: 3602–3607
Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA (1994) Heart muscle disease related to HIV infection: prognostic implications. BMJ 309: 1605–1607
Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al (1998) Platelet derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11: 554–559
Cohen IS, Anderson DW, Virmani R, Reen BM, Macher AM, Sennesh J, et al (1986) Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 315: 628–630
Herskowitz A, Wu TC, Willoughby SB, Vlahov D, Ansari AA, Beschorner WE, et al (1994) Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 24: 1025–1032
De Castro S, d'Amati G, Gallo P, Cartoni D, Santopadre P, Vullo V, et al (1994) Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 24: 1018–1024
Herskowitz A, Vlahov D, Willoughby S, Chaisson RE, Schulman SP, Neumann DA, et al (1993) Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 71: 955–958
Barbarini G, Barbaro G (2003) Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 17: S46–S50
Jacob AJ, Sutherland GR, Bird AG, Brettle RP, Ludlam CA, McMillan A, et al (1992) Myocardial dysfunction in patients infected with HIV: prevalence and risk factors. Br Heart J 68: 549–553
Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al (1998) Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 97: 1246–1256
Lewis W (1989) AIDS: cardiac findings from 115 autopsies. Prog Cardiovasc Dis 32: 207–215
Mesa RA, Edell ES, Dunn WF, Edwards WD (1998) Human immunodeficency virus infection and pulmonary hypentension. Mayo Clin Proc 73: 37–44
Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR (2004) Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 4: 117–131
Kaminski HJ, Katzman M, Wiest PM, Ellner JJ, Gifford DR, Rackley R, et al (1988) Cardiomyopathy associated with the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr 1: 105–110
Lipshultz SE, Orav EJ, Sanders SP, Colan SD (1995) Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 92: 2220–2225
Zareba KM, Lipshultz SE (2003) Cardiovascular complications in patients with HIV infection. Curr Infect Dis Rep 5: 513–520
Barbaro G (2005) Reviewing the cardiovascular complications of HIV Infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 5: 337–343
Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D (2000) Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 40: 282–284
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sani, M. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr 120, 77–87 (2008). https://doi.org/10.1007/s00508-008-0935-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00508-008-0935-3